We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




New Surface Disinfectant Fights MRSA

By HospiMedica staff writers
Posted on 13 Sep 2006
A new silver-based hard surface disinfectant kills deadly methicillin-resistant Staphyloccocus aureus (MRSA) in just two minutes.

The new disinfectant, called Staph Attack, is based on silver dihydrogen citrate (SDC), an electrolytically generated source of stabilized ionic silver. More...
While traditional silver-based disinfectants have very short shelf lives (from hours to days), SDC has a shelf life of several years. The unique bond of the silver ion in SDC allows the silver ion to remain in solution while at the same time making it more bio-available for antimicrobial action.

SDC kills microorganisms by two modes of action: (1) the silver ion deactivates structural and metabolic membrane proteins leading to microbial death; (2) the microbes view SDC as a food source, allowing the silver ion to enter the microbe. Once inside the organism, the silver ion denatures the DNA, which halts the microbe's ability to replicate and leads to its death. This dual action makes SDC highly and quickly effective against a broad spectrum of microbes. SDC is colorless, odorless, tasteless, non-caustic, formulates well with other compounds, and bacteria are unable to form a resistance to it.

Staph Attack provides broad spectrum protection as a disinfectant, fungicide, and virucide, and provides residual protection for 24 hours. It has been specifically formulated for closed populations where resistant bacteria are becoming increasingly problematic, such as hospitals, prisons, and schools. The hard surface disinfectant U.S. EPA (Environmental Protection Agency) registration includes a 30-second kill time on standard indicator bacteria, a 24-hour residual kill on standard indicator bacteria, a two-minute kill time on some resistant strains of bacteria, a 10-minute kill time on fungi, a 30-second kill time on HIV type I, and a 10-minute kill time on other pathogenic viruses. It carries an EPA category IV toxicity rating, the lowest available.

Staph Attack is the product of Pure Bioscience (El Cajon, CA, USA).



Related Links:
Pure Bioscience

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.